ALLMedicine™ Acute Lymphoblastic Leukemia Center

Apr 9th, 2021 - Strongyloides stercoralis hyperinfection in a patient with acute lymphoblastic leukemia.|2021|Mishra S,Patnayak R,Panda SS,Jena A,|

Apr 9th, 2021 - BACKGROUND A rapid investigation of dengue viral infection is needed for physicians who manage patients with suspected dengue infection. The nonstructural protein 1 (NS1) test kit is commonly used to diagnose patients with acute febrile illness in...

Apr 8th, 2021 - Allogeneic hematopoietic cell transplantation (HCT) can offer cure to some patients with acute lymphoblastic leukemia (ALL). It remains unclear how conditioning intensity affects transplant outcomes in ALL. In this retrospective study, we compared...

Apr 8th, 2021 - The association between mature B-cell phenotype and KMT2A rearrangements in acute lymphoblastic leukemia is a very rare finding. It identifies a group of patients with similar clinical and biological characteristics that clearly differs from the e...

Apr 8th, 2021 - B-cell lymphoma 2 (BCL-2) has recently emerged as a therapeutic target for early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL), a high-risk subtype of human T-cell ALL. The major clinical challenge with targeted therapeutics, such as th...

Jan 13th, 2021 - ALL (also called acute lymphocytic leukemia) is an aggressive type of leukemia characterized by the presence of too many lymphoblasts or lymphocytes in the bone marrow and peripheral blood. It can spread to the lymph nodes, spleen, liver, central ...

May 30th, 2020 - Children with Down syndrome and acute lymphoblastic leukemia continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program.

May 28th, 2020 - Application of a set of stringent clinical and cytogenetic features as well as minimal residual disease (MRD) criteria can identify a subset of low-risk (LR) pediatric patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who can...

May 12th, 2020 - In pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) who received prior blinatumomab exposure or inotuzumab ozogamicin as bridging therapy, treatment with tisagenlecleucel is associated with consistent ...

Jan 7th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

Apr 9th, 2021 - Strongyloides stercoralis hyperinfection in a patient with acute lymphoblastic leukemia.|2021|Mishra S,Patnayak R,Panda SS,Jena A,|

Apr 9th, 2021 - BACKGROUND A rapid investigation of dengue viral infection is needed for physicians who manage patients with suspected dengue infection. The nonstructural protein 1 (NS1) test kit is commonly used to diagnose patients with acute febrile illness in...

Apr 8th, 2021 - Allogeneic hematopoietic cell transplantation (HCT) can offer cure to some patients with acute lymphoblastic leukemia (ALL). It remains unclear how conditioning intensity affects transplant outcomes in ALL. In this retrospective study, we compared...

Apr 8th, 2021 - The association between mature B-cell phenotype and KMT2A rearrangements in acute lymphoblastic leukemia is a very rare finding. It identifies a group of patients with similar clinical and biological characteristics that clearly differs from the e...

Apr 8th, 2021 - B-cell lymphoma 2 (BCL-2) has recently emerged as a therapeutic target for early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL), a high-risk subtype of human T-cell ALL. The major clinical challenge with targeted therapeutics, such as th...

Mar 24th, 2021 - The use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival in minimal residual disease (MRD)-negative remission patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) after the start...

Mar 2nd, 2021 - NEW YORK (Reuters Health) - Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia (B-ALL), with improved outcomes and a favo...

Feb 2nd, 2021 - For now at least, total body irradiation (TBI) plus etoposide remains the conditioning regimen of choice for children undergoing allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia (ALL), according to an open-label phase...

Jan 13th, 2021 - ALL (also called acute lymphocytic leukemia) is an aggressive type of leukemia characterized by the presence of too many lymphoblasts or lymphocytes in the bone marrow and peripheral blood. It can spread to the lymph nodes, spleen, liver, central ...

Oct 20th, 2020 - The days of using chemotherapy to treat Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) may be numbered. In a phase 2 trial, up-front chemo-free induction/consolidation with the tyrosine kinase inhibitor dasatinib (Sprycel)...